We reviewed 82 patients with 83 upper urinary tract tumors and investigated those who had associated bladder tumors. Of these patients, 7 (9%) had previous bladder tumors, 14 (17%) had concurrent bladder tumors, and 18 (22%) subsequently developed bladder tumors. As 1 patient subsequently developed a bladder and a upper urinary tract tumor at different times, 38 patients (46%) had associated bladder tumors. The time interval between the occurrence of a previous bladder tumor and the subsequent upper urinary tract tumor was 11 to 144 months (mean: 41 months), while that between an upper urinary tract tumor and the subsequent bladder tumor was 3–31 months (mean: 12 months). Most of the previous bladder tumors were papillary, multiple, and noninvasive (pT1 or less). Multiple upper urinary tract tumors were associated with a high incidence of concurrent bladder tumors, while high-grade (G2, G3) or invasive (pT2 or more) upper urinary tract tumors were associated with a high incidence of concurrent and subsequent bladder tumors. Patients with concurrent bladder tumors had a worse prognosis than those with previous or subsequent bladder tumors due to the increased incidence of high-stage tumors at either the upper tract or bladder site. Our findings suggest that tumor cell implantation is a possible mechanism for the recurrence of bladder tumors and upper urinary tract tumors.

Keywords:
Upper urinary tract tumor, Bladder tumor, Risk factor, Recurrence, Tumor cell implantation, Prognosis
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.